Eisai Co., Ltd. announced the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment… read more.
ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
